Selina Chiu, Helen Staley, Priya Jeevananthan, Sophie Mascarenhas, Christina Fotopoulou, Andrea Rockall
{"title":"Ovarian Cancer Screening: Recommendations and Future Prospects.","authors":"Selina Chiu, Helen Staley, Priya Jeevananthan, Sophie Mascarenhas, Christina Fotopoulou, Andrea Rockall","doi":"10.1055/a-2589-5696","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer remains a significant cause of mortality among women, largely due to challenges in early detection. Current screening strategies, including transvaginal ultrasound and CA125 testing, have limited sensitivity and specificity, particularly in asymptomatic women or those with early-stage disease. The European Society of Gynaecological Oncology, the European Society for Medical Oncology, the European Society of Pathology, and other health organizations currently do not recommend routine population-based screening for ovarian cancer due to the high rates of false-positives and the absence of a reliable early detection method.This review examines existing ovarian cancer screening guidelines and explores recent advances in diagnostic technologies including radiomics, artificial intelligence, point-of-care testing, and novel detection methods.Emerging technologies show promise with respect to improving ovarian cancer detection by enhancing sensitivity and specificity compared to traditional methods. Artificial intelligence and radiomics have potential for revolutionizing ovarian cancer screening by identifying subtle diagnostic patterns, while liquid biopsy-based approaches and cell-free DNA profiling enable tumor-specific biomarker detection. Minimally invasive methods, such as intrauterine lavage and salivary diagnostics, provide avenues for population-wide applicability. However, large-scale validation is required to establish these techniques as effective and reliable screening options. · Current ovarian cancer screening methods lack sensitivity and specificity for early-stage detection.. · Emerging technologies like artificial intelligence, radiomics, and liquid biopsy offer improved diagnostic accuracy.. · Large-scale clinical validation is required, particularly for baseline-risk populations.. · Chiu S, Staley H, Jeevananthan P et al. Ovarian Cancer Screening: Recommendations and Future Prospects. Rofo 2025; DOI 10.1055/a-2589-5696.</p>","PeriodicalId":21490,"journal":{"name":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2589-5696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Ovarian cancer remains a significant cause of mortality among women, largely due to challenges in early detection. Current screening strategies, including transvaginal ultrasound and CA125 testing, have limited sensitivity and specificity, particularly in asymptomatic women or those with early-stage disease. The European Society of Gynaecological Oncology, the European Society for Medical Oncology, the European Society of Pathology, and other health organizations currently do not recommend routine population-based screening for ovarian cancer due to the high rates of false-positives and the absence of a reliable early detection method.This review examines existing ovarian cancer screening guidelines and explores recent advances in diagnostic technologies including radiomics, artificial intelligence, point-of-care testing, and novel detection methods.Emerging technologies show promise with respect to improving ovarian cancer detection by enhancing sensitivity and specificity compared to traditional methods. Artificial intelligence and radiomics have potential for revolutionizing ovarian cancer screening by identifying subtle diagnostic patterns, while liquid biopsy-based approaches and cell-free DNA profiling enable tumor-specific biomarker detection. Minimally invasive methods, such as intrauterine lavage and salivary diagnostics, provide avenues for population-wide applicability. However, large-scale validation is required to establish these techniques as effective and reliable screening options. · Current ovarian cancer screening methods lack sensitivity and specificity for early-stage detection.. · Emerging technologies like artificial intelligence, radiomics, and liquid biopsy offer improved diagnostic accuracy.. · Large-scale clinical validation is required, particularly for baseline-risk populations.. · Chiu S, Staley H, Jeevananthan P et al. Ovarian Cancer Screening: Recommendations and Future Prospects. Rofo 2025; DOI 10.1055/a-2589-5696.
期刊介绍：
Die RöFo veröffentlicht Originalarbeiten, Übersichtsartikel und Fallberichte aus dem Bereich der Radiologie und den weiteren bildgebenden Verfahren in der Medizin. Es dürfen nur Arbeiten eingereicht werden, die noch nicht veröffentlicht sind und die auch nicht gleichzeitig einer anderen Zeitschrift zur Veröffentlichung angeboten wurden. Alle eingereichten Beiträge unterliegen einer sorgfältigen fachlichen Begutachtung.
Gegründet 1896 – nur knapp 1 Jahr nach der Entdeckung der Röntgenstrahlen durch C.W. Röntgen – blickt die RöFo auf über 100 Jahre Erfahrung als wichtigstes Publikationsmedium in der deutschsprachigen Radiologie zurück. Sie ist damit die älteste radiologische Fachzeitschrift und schafft es erfolgreich, lange Kontinuität mit dem Anspruch an wissenschaftliches Publizieren auf internationalem Niveau zu verbinden. Durch ihren zentralen Platz im Verlagsprogramm stellte die RöFo die Basis für das heute umfassende und erfolgreiche Radiologie-Medienangebot im Georg Thieme Verlag.
Besonders eng verbunden ist die RöFo mit der Geschichte der Röntgengesellschaften in Deutschland und Österreich. Sie ist offizielles Organ von DRG und ÖRG und die Mitglieder der Fachgesellschaften erhalten die Zeitschrift im Rahmen ihrer Mitgliedschaft. Mit ihrem wissenschaftlichen Kernteil und dem eigenen Mitteilungsteil der Fachgesellschaften bietet die RöFo Monat für Monat ein Forum für den Austausch von Inhalten und Botschaften der radiologischen Community im deutschsprachigen Raum.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
